anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
New aminooxylipids of general formula (I), wherein n= 5-30 and X is a polymethylene linker of the general formula (II) where n= 2 -10, or X is a polyethylene glycol linker of the general formula (III), wherein n= 1-14. A method of preparation of the aminooxylipids of general formula (I) characterized in that the acylation of-butoxycarbonyl-polymethylenediamine, or- butoxycarbonyl-polyethyleglycoldiamine in position C(2) symmetrically branched fatty acids of general formula (IV), in the presence of a condensation reagent, or from acid of general formula (I) derived acylchloride of general formula (V) produces-aminolipids of general formula (VI). These are converted to aminolipids of general formula (VII). By their condensation with-butoxycarbonyl-aminooxyacetic acid in the presence of condensation reagent,-aminooxylipids of general formula (VIII), which by debocylation afford aminooxylipids of general formula (I). Acylchlorides of general formula (V) are prepared by reaction of acid of general formula (IV) with oxalylchloride in the presence of catalytic amount of-dimethylformamide in an organic aprotic solvent.  The use of nontoxic aminooxylipids of the general formula I for construction of nontoxic self-assembly liposomal carriers of therapeutics presenting aminooxy groups and so-called "post-liposomal" modification of these carriers with biologically functional molecules using oxime ligation technique.
The invention relates to a Seneca Valley virus VP1 protein, a coding gene, a hybridoma cell strain, a monoclonal antibody and application thereof, belonging to the technical field of viruses. The Sagnac Valley virus Hubei strain VP1 protein is used as the antigen protein of Sagnac Valley virus in the application of immunoassay. The invention provides a hybridoma cell strain 2G6 secreting monoclonal antibody against the protein of the Seneca Valley virus Hubei strain VP1 of claim 1, wherein the preservation number of the hybridoma cell strain is CCTCC NO: C2017226. The monoclonal antibody is secreted by the hybridoma cell strain 2G 6. The monoclonal antibody is applied to immunological binding of the protein of Hubei strain VP1 of Seneca valley virus. The invention provides application of the monoclonal antibody in a kit for blocking cells infected by Hubei strain of Seneca valley virus.
BACKGROUND: Children who are critically ill are often reliant on enteral and oral nutrition support. However, there is limited evidence to guide "what" to prescribe, and current practice is unknown. The primary objective of this study was to describe enteral nutrition prescription in children ≤2 years of age in the pediatric intensive care unit (PICU). The secondary objectives were to describe oral nutrition support practices and factors associated with the use of increased energy and protein density nutrition support.
METHODS: Children ≤2 years of age admitted to participating PICUs over a 2-week period in June 2021 were enrolled. Data were collected on PICU admission days 1 to 7, 14, 21, and 28 on the mode of nutrition, enteral and oral nutrition support prescription, and dietitian intervention.
RESULTS: Eighty-four children were included (49 [58%] male; 79 [94%] ≤1 year of age). Enteral nutrition was administered to 79 (94%) children (with expressed breast milk in 45 [57%]). Forty-three children received formula as enteral nutrition. Increased energy and protein density formulas were provided to 14 (33%) children enterally, with concentrated standard infant formula powder being the most common (5 [12%]). Among children offered oral intake (22; 26%), three (14%) received oral nutrition support. Children who received increased energy and protein density enteral nutrition were more likely to receive dietitian intervention (P = 0.002).
CONCLUSION: In children ≤2 years of age admitted to PICU, expressed breast milk was provided to half of those requiring enteral nutrition and oral nutrition support prescription was infrequent. One third of children receiving formula via enteral nutrition received an increased energy and protein density feed, and this was strongly associated with dietitian intervention.
Patients receive clostridium butyricum CBM 588 probiotic strain PO BID, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, treatment with clostridium butyricum CBM 588 probiotic strain and nivolumab repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Cleviprex is intended for intravenous use. Titrate drug to achieve the desired blood pressure reduction. Individualize dosage depending on the blood pressure to be obtained and the response of the patient.

Initial dose: Initiate the intravenous infusion of Cleviprex at 1-2 mg/hour.

Dose titration: The dose may be doubled at short (90 second) intervals initially. As the blood pressure approaches goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. An approximately 1-2 mg/hour increase will generally produce an additional 2-4 mmHg decrease in systolic pressure.

Maintenance dose: The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Patients with severe hypertension may require doses up to 32 mg/hour, but there is limited experience at this dose rate.

Maximum dose: Most patients were treated with maximum doses of 16 mg/hour or less.There is limited short-term experience with doses up to 32 mg/hour. Because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Cleviprex infusion is recommended per 24 hour period. In clinical trials, 55 hypertensive patients were treated with >500mL of Cleviprex infusion per 24 hour period. There is little experience with infusion durations beyond 72 hours at any dose.

Transition to an oral antihypertensive agent: Discontinue Cleviprex or titrate downward while appropriate oral therapy is established. When an oral antihypertensive agent is being instituted, consider the lag time of onset of the oral agent’s effect. Continue blood pressure monitoring until desired effect is achieved.
Healthy Living (HL) will consist of six, 45-60 minute sessions delivered one-on-one; sessions 1-3 in-person on HCT unit and sessions 4-6 via video conference. HL will be based on the American Cancer Society's (ACS) Caregiver Resource Guide.
BACKGROUND: Malaria remains a significant public health concern, especially for the deadliest parasite, Plasmodium falciparum. During acute malaria, various cytokines, including osteopontin (OPN), regulate the immune response. OPN has been shown to be protective against malaria in mice. Nonetheless, its precise function and potential ability to control parasites during acute malaria in humans remain poorly understood.
RESULTS: Blood samples were collected from Swedish adults with imported malaria, Ugandan children and adults with symptomatic malaria (including follow-up after 42 days), Ugandans with non-malarial fever and healthy individuals from both Uganda and Sweden. Parasitemia was determined by microscopy. Malaria-negative samples were verified by LAMP. OPN and interferon-γ (IFN- γ) levels were measured using ELISA. In children, OPN levels were significantly higher during acute infection compared to levels after 42 days, whereas Ugandan adults showed no difference. Swedish adults with imported malaria had elevated OPN levels compared to both Swedish controls and Ugandan adults with malaria. Parasitemia was significantly correlated with both OPN and IFN-γ levels across the entire cohort. While a significant correlation between OPN and IFN-γ was evident overall, it remained statistically significant only in Ugandan adults when analyzed by subgroups. This suggests that OPN is not just a general marker of inflammation but may be regulated differently during the development of malaria immunity.
CONCLUSIONS: In acute malaria, elevated OPN levels showed a stronger correlation with lack of immunity than age. These findings underscore the potential importance of OPN in malaria, particularly in non-immune individuals.
Teratogenic Effects: Pregnancy Category B

There are no adequate or well-controlled studies in pregnant women. Therefore, ciclopirox cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. Ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 11, 37, 51 and 24 times the maximum recommended human dose based on body surface area comparisons, respectively).

Dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in PEG 400. Ciclopirox olamine was topically administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 92 mg/kg/day and 77 mg/kg/day ciclopirox in rats and rabbits, respectively (approximately 27 and 49 times the maximum recommended human dose based on body surface area comparisons, respectively).
Patients randomised to the investigational arm will receive transcutaneous oestrogen patches (100 micrograms/24 hours). Treatment should be planned to continue for at least 3 years. For patients prescribed bicalutamide or flutamide prior to randomisation, this treatment should be discontinued before treatment with the patches can commence (no washout period is needed).
Blood levels of homocysteine are elevated in Alzheimer's disease (AD), and hyperhomocysteinemia may contribute to disease pathophysiology by vascular and direct neurotoxic mechanisms. Homocysteine levels can be reduced by administration of high dose supplements of folate (folic acid) and vitamins B6 and B12. The proposed study is for a multicenter, randomized, controlled clinical trial to determine whether reduction of homocysteine levels with high-dose folate/B6/B12 supplementation will slow the rate of cognitive decline in subjects with AD.

This will be a parallel design study, including two groups of unequal size: 60% of subjects will receive daily high-dose supplements (folate 5mg, vitamin B6 25mg, vitamin B12 1 mg), and 40% will receive an identical looking placebo. The duration of treatment will be 18 months, and participants will make eight visits to the assigned study site for safety and efficacy assessments of the medications. The primary outcome measure will be the longitudinal decline in the ADAScog, a psychometric instrument that evaluates memory, attention, reasoning, language, orientation and praxis (Rosen et al 1984). To power the trial to detect a 25% reduction in rate of ADAScog decline (80% power, alpha=0.05, drop-out estimate 20%, drop-in estimate 10%), it will enroll a total of 400 participants. Persons of minority racial groups are also being recruited, although all participants must be able to speak either English or Spanish.
FIELD: medicine, neurology. SUBSTANCE: human basic myelin protein has molecular mass 18.5 kDa and consists of 170 amino acid residues. Obtained synthetic peptides have length at the range from 8 to 25 residues and embrace the total protein molecule length. Antibodies to human basic myelin protein were neutralized with synthetic peptides that embrace by length 61-106 amino acid residues of myelin protein. Synthetic peptides that embrace both amine (1-63 residues) and carboxylic (117-162) terminal groups of myelin protein do not neutralize the purified antibodies to human myelin protein. It is possible to use intrathecal utilization of selective synthetic peptides of human basic myelin protein for multiple sclerosis treatment. EFFECT: enhanced effectiveness of treatment.
Patients having gastric band, sleeve gastrectomy, and gastric bypass will have blood and urine tests, and 51 Cr-EDTA clearance to assess renal function. These are taken before and after the surgery at 6 weeks , 6 months and 12 months.
The invention provides a pharmaceutical composition containing a cefmetazole sodium compound. The pharmaceutical composition is prepared from cefmetazole acid, sodium carbonate and mannitol. The invention also provides a preparation method of the pharmaceutical composition containing the cefmetazole sodium compound. The preparation method comprises the following steps of: adding the active component cefmetazole acid sterile powder, the cosolvent sodium carbonate and the excipient mannitol to water for injection, adding active carbon and stirring, regulating the pH to be 6 by sodium hydroxide, filtering to remove the active carbon, finely filtering by a filter membrane, filling and lyophilizing. Because a proper amount of excipient mannitol is added to the pharmaceutical composition prepared by the method, the lyophilized powder is more stable in quality and can be stored for a long term. The cefmetazole acid and the sodium carbonate directly react to obtain the cefmetazole sodium, thereby shortening the process flow.
After proper positioning and local infiltration, a linear high-frequency ultrasound transducer will be placed on the anteromedial aspect of the neck, approximately 2 cm above the clavicle, and the interscalene brachial plexus will be identified between the anterior and middle scalene muscles. After sterile preparation of the skin, a 22-gauge needle will be inserted in-plane from the lateral aspect of the transducer and directed through the middle scalene muscle. The needle will be advanced until the tip is observed just lateral to the brachial plexus sheath. After negative aspiration, 20mL of 0.5% bupivacaine will be injected in 5mL increments, followed by 20mL of Exparel injected in 5mL increments. The injection will be administered slowly with periodic aspiration, with the needle being adjusted using ultrasound guidance as the ISB is injected to surround the brachial plexus trunks (upper, middle and lower) that are seen at the interscalene level of injection.
Participants will receive tremelimumab 75 mg Q4W 4 doses and durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first. Participant recruitment to this arm was closed following protocol amendment 5.
Participants received DOVATO (DTG 5 mg/3TC 30 mg), dispersible tablets administered as a dispersion immediately after a high calorie meal (under fed condition) (Treatment C) in treatment period 1 followed by DOVATO (DTG 5 mg/3TC 30 mg), dispersible tablets administered as a dispersion under fasted conditions (Treatment D) in treatment period 2. The treatment periods were separated by a washout period of about 7 days. All participants were followed-up for 7 to 14 days of last dose in treatment period 2.
Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the bone cement is prepared to simulate the odor associated with mixing of polymethacrylate , but the needle is not placed and cement is not injected.
PURPOSE: A makeup cosmetic composition using scoria powder is provided to have various functionalities such as UV protection, moisturization, far-infrared ray irradiation, and heavy metal adsorption. CONSTITUTION: A makeup cosmetic composition contains 60 wt% or more of scoria powder as a pigment. The particle size of the scoria powder is 5 micrometer or less. A cosmetic composition for UV protection further contains an extract selected from the group consisting of a Weigela subsessilis leaf extract, a Rhododendron weyrichii leaf extract, and a Vaccinium oldhami leaf extract. The extracts are prepared using water. The composition contains 2-10 wt% of the extract of a powder phase.
Severe diarrhea occurred in 25% of patients treated with FARYDAK [see Adverse Reactions (6.1)]. Diarrhea of any grade occurred in 68% of patients treated with FARYDAK compared to 42% of patients in the control arm. Diarrhea can occur at any time. Monitor patient hydration status and electrolyte blood levels, including potassium, magnesium and phosphate, at baseline and weekly (or more frequently as clinically indicated) during therapy and correct to prevent dehydration and electrolyte disturbances. Initiate anti-diarrheal medication at the onset of diarrhea. Interrupt FARYDAK at the onset of moderate diarrhea (4 to 6 stools per day) [see Dosage and Administration (2.3)]. Ensure that patients initiating therapy with FARYDAK have anti-diarrheal medications on hand.
A water-soluble supramolecular complex is formed from a water-soluble block copolymer and at least one associative gel adjuvant. The copolymer comprises at least two polyethylene oxide blocks and at least one polypropylene oxide block. The adjuvant has a water solubility of less than 0.5g/100ml at 20 ℃. When combined with water, the complex forms a transparent reverse thermosensitive reversible hydrogel or solution that can be repeatedly hydrated or dehydrated. The hydrogels exhibit improved gel efficacy and improved solubility and/or stability for poorly soluble or insoluble pharmaceutical agents. The complexes are useful in a variety of pharmaceutical and cosmetic products and applications, and may be combined with an effective amount of a cosmetic, pharmaceutical or diagnostic agent in solid dosage form.
This study aimed to examine the association of Mediterranean diet (MD) adherence and MD components with health-related quality of life (HRQoL) in pregnant women from Spain and Sweden. A total of 138 pregnant women from Spain (age: 32.9 ± 4.6 years old) and 302 pregnant women from Sweden (age: 31.3 ± 4.1 years old) were included. MD adherence was assessed with the Mediterranean food pattern (i.e., a MD index) at the 14-16th gestational weeks. HRQoL was assessed with the Spanish and Swedish versions of the 36-item Short-Form Health Survey (SF-36 and RAND-36, respectively) at the 14-16th and 34-37th gestational weeks. A greater MD adherence was associated with better physical functioning, bodily pain, vitality, emotional role, and mental health in cross-sectional associations (2nd trimester) in the Spanish sample (all p < 0.05). Furthermore, a greater MD adherence was associated with lower bodily pain in both Spanish and Swedish samples (both p < 0.05) in the 3rd trimester. The associations of MD adherence with pain seem to be explained by a greater intake of fiber, fish, fruits, nuts, and legumes (all p < 0.05). A greater MD adherence, driven by a higher intake of fiber, fish, fruits, nuts, and legumes, was associated with lower pain throughout pregnancy in both Mediterranean and non-Mediterranean populations.
PURPOSE:To provide a cerebral circulatory metabolism-improving agent having a stronger cerebral circulatory metabolism-improving action than when idebenone or vinpocetine is singly used and effective for treating and improving the aftereffects of cerebral infarction, etc., of mammals including human beings by combining the idebenone and the vinpocetine. CONSTITUTION:The agent contains idebenone of formula I and vinpocetine of formula II as active ingredients. The idebenone has an immunostimulative action and a histo-metabolism activating action in an organism and the vinpocetine has an erythrocyte deformation-accelerating action, etc. Both the active ingredients are singly or together mixed with a pharmacologically acceptable additive (e.g., extender or diluent) to provide a suitable medical composition. When the active ingredients are used as the separated compositions, the compositions can be combined. Since both the active ingredients are slightly soluble in water, a dissolution aid is preferably used for preparing aqueous injections.
In multiple neurodegenerative diseases, including age-related macular degeneration, retinitis pigmentosa, and macular telangiectasia type 2 (MacTel), retinal pigment epithelial (RPE)-cells proliferate and migrate into the neuroretina, forming intraretinal pigment plaques. Though these pigmentary changes are hallmarks of disease progression, it is unknown if their presence is protective or detrimental.Here, we first evaluated the impact of pigment plaques on vascular changes and disease progression in MacTel. In a retrospective, longitudinal study, we analyzed multimodal retinal images of patients with MacTel and showed that pigment plaques were associated with decreased vascular leakage and stabilized neovascular growth. We then modeled the underlying pathomechanisms of pigment plaque formation in aberrant neovascular growth using the very-low-density lipoprotein receptor mutant (Vldlr-/-) mouse. Our data indicated that during RPE-proliferation, migration and accumulation along neovessels RPE-cells underwent epithelial-mesenchymal transition (EMT). Pharmacologic inhibition of EMT in Vldlr-/- mice decreased pigment coverage, and exacerbated neovascular growth and vascular leakage.Our findings indicate that the proliferation, migration and perivascular accumulation of RPE-cells stabilize vascular proliferation and exudation, thereby exerting a protective effect on the diseased retina. We conclude that interfering with this "natural repair mechanism" may have detrimental effects on the course of the disease and should thus be avoided.
Ascorbic acid \[AA\] (vitamin C) is an essential nutrient that, in addition to aiding tissue repair, also functions as an enzyme co-factor, an antioxidant, and a key component in lymphocyte development and function. Lymphocytes are responsible for adaptive immunity, the immune response following vaccination, in addition to playing a vital role in protection against viral disease progression. Both sepsis and aberrant lymphocyte activation have been associated with severe AA deficiency. We hypothesize that the administration of increasing concentrations of pharmacologic AA promotes lymphocyte activation and signaling in newly admitted, non-ventilator dependent COVID-19 patients via hydrogen peroxide generation and/or DNA de-methylation, and that this will lead to improved clinical outcomes.

This is a single-center, prospective, randomized, open-label, phase II clinical trial designed to assess the efficacy, tolerability, and safety of pharmacologic AA administration in hospitalized patients newly-diagnosed with COVID-19 who will likely not require mechanical ventilation within 24 hours of study intervention. All subjects enrolled will be pending inpatient admission or already admitted as they will require supplemental oxygen. Within 12 hours of admission to the E.D. or medical/surgical floor (rapid screens to determine eligibility must be completed within this time), patients will receive escalating pharmacologic AA over 2 hours once daily for 3 escalating doses, then continued on the highest dose for a total of 6 infusions.

Subjects will be randomized 2:1, with 66 subjects receiving AA treatments and 22 subjects receiving routine clinical care. The open-label design allows investigators to evaluate the safety and clinical progress in real-time. Any subject randomized to AA treatment who is upgraded to ICU-level care, requires high-flow O2 supplementation, or is intubated, will no longer receive AA infusions in order to maximize patient safety during this study. Given the robust safety data on the treatment, a phase II design was chosen with an interim safety analysis after 21 patients. Randomization will be stratified according to high vs. low risk of complications. Patients will be considered to be high risk if they have any of the following characteristics: age\>60, hypertension, structural lung disease, cardiovascular disease, diabetes, immunocompromising conditions or meds (such as immunosuppressing meds in transplant patients).